<DOC>
	<DOCNO>NCT01981616</DOCNO>
	<brief_summary>The primary purpose study determine rate seroconversion hepatitis B vaccine series single 750 mg intravenous ( IV ) dose vedolizumab placebo . Secondary objective determine rate seroconversion oral cholera vaccine series , assess change anti-hepatitis B surface antibody assess safety tolerability single 750-mg IV dose vedolizumab .</brief_summary>
	<brief_title>Immune Response Systemic Mucosal Antigenic Challenge Presence Vedolizumab</brief_title>
	<detailed_description />
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Vedolizumab</mesh_term>
	<criteria>Inclusion criterion 1 . Male female participant 18 39 year age . 2 . Body mass index ( BMI ) 18 32 kg/m^2 , inclusive . 3 . Females : postmenopausal least 1 year Screening visit , OR ; surgically sterile , OR ; childbearing potential , agree practice 2 effective method contraception , time , time signing inform consent 6 month last dose study drug , agree completely abstain heterosexual intercourse . 4 . Males , even surgically sterilize ( ie , status postvasectomy ) , : agree practice effective barrier contraception entire study treatment period 6 month last dose study drug , ; agree completely abstain heterosexual intercourse . 5 . Is willing able provide write informed consent comply study requirement . 6 . Has suitable venous access studyrequired infusion blood sample . Exclusion criteria 1 . Known exposure hepatitis B virus . 2 . Known prior hepatitis B vaccination , irrespective number dos receive , previous employment healthcare set . 3 . Seropositivity prior hepatitis B infection hepatitis B vaccination Screening period . 4 . Known exposure cholera prior Dukoral exposure , irrespective number dos receive . 5 . History major cardiovascular , pulmonary , hepatic , renal , gastrointestinal ( GI ) , genitourinary , hematological , immunological , psychiatric , major medical disorder . 6 . History major neurological disorder , include stroke , multiple sclerosis , brain tumor , neurodegenerative disease , neurological disorder would confound neurological examination , result subjective objective progressive multifocal leukoencephalopathy ( PML ) checklist study . 7 . Any history coagulation disorder , history current use anticoagulation therapy ( eg , warfarin , heparin ) . 8 . Any disorder require chronic regular use form corticosteroid ( include limited topical , intranasal , rectal , etc ) , immunomodulator ( eg , azathioprine ) therapy , immunosuppressant ( eg , mycophenolate , tacrolimus , tumor necrosis factoralpha ( TNFÎ± ) antagonist ) . 9 . Regular use herbal , homeopathic natural supplement include limited putative immune stimulant . Participants must use agent within 30 day enrollment . 10 . Female participant lactate positive serum pregnancy test Screening period positive urine pregnancy test Day 1 predose ; woman consider become pregnant study exclude . 11 . Acute illness within precede 30 day , opinion investigator , could pose threat harm participant obscure laboratory test result interpretation data exposure vedolizumab ( eg , mononucleosis ) . 12 . Any history malignancy , except follow : ( ) adequatelytreated nonmetastatic basal cell skin cancer ; ( b ) squamous cell skin cancer adequately treat recur least 1 year prior enrollment ; ( c ) history cervical carcinoma situ adequately treat recur least 3 year enrollment . 13 . Had surgical procedure require general anesthesia within 30 day initial Screening visit planning undergo surgery require general anesthesia study period . Minor surgery medically necessary require general anesthesia may allowable study period . 14 . One positive response PML subjective symptom checklist screen dose Day 1 . 15 . Blood donation within 60 day screen . 16 . Unable attend study day comply protocol requirement . 17 . Any reason , opinion investigator , would confound conduct study interpretation result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>